246 related articles for article (PubMed ID: 34079092)
1. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
[TBL] [Abstract][Full Text] [Related]
2. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
3. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.
Goltz D; Gevensleben H; Vogt TJ; Dietrich J; Golletz C; Bootz F; Kristiansen G; Landsberg J; Dietrich D
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997292
[TBL] [Abstract][Full Text] [Related]
4. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract][Full Text] [Related]
5. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
6. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D; Schilling B; Liu D; Sucker A; Livingstone E; Jerby-Arnon L; Zimmer L; Gutzmer R; Satzger I; Loquai C; Grabbe S; Vokes N; Margolis CA; Conway J; He MX; Elmarakeby H; Dietlein F; Miao D; Tracy A; Gogas H; Goldinger SM; Utikal J; Blank CU; Rauschenberg R; von Bubnoff D; Krackhardt A; Weide B; Haferkamp S; Kiecker F; Izar B; Garraway L; Regev A; Flaherty K; Paschen A; Van Allen EM; Schadendorf D
Nat Med; 2019 Dec; 25(12):1916-1927. PubMed ID: 31792460
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
8. T cell immune awakening in response to immunotherapy is age-dependent.
Salih Z; Banyard A; Tweedy J; Galvani E; Middlehurst P; Mills S; Weightman J; Gupta A; Lorigan PC; Zhou C; Dhomen N; Valpione S; Marais R
Eur J Cancer; 2022 Feb; 162():11-21. PubMed ID: 34952479
[TBL] [Abstract][Full Text] [Related]
9. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
Kaptein P; Jacoberger-Foissac C; Dimitriadis P; Voabil P; de Bruijn M; Brokamp S; Reijers I; Versluis J; Nallan G; Triscott H; McDonald E; Tay J; Long GV; Blank CU; Thommen DS; Teng MWL
Sci Transl Med; 2022 Apr; 14(642):eabj9779. PubMed ID: 35476594
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
12. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
Gong X; Karchin R
Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
[TBL] [Abstract][Full Text] [Related]
13. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
14. A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.
Kumar N; Papillon-Cavanagh S; Tang H; Wang S; Stromko C; Ho CP; Soni-Sheth S; Vasquez-Grinnell S; Broz ML; Tenney DJ; Wichroski MJ; Walsh AM; Hu Y; Benci JL
Int J Cancer; 2022 Dec; 151(11):2043-2054. PubMed ID: 35932450
[TBL] [Abstract][Full Text] [Related]
15. Human CXCR5
Hofland T; Martens AWJ; van Bruggen JAC; de Boer R; Schetters S; Remmerswaal EBM; Bemelman FJ; Levin MD; Bins AD; Eldering E; Kater AP; Tonino SH
Eur J Immunol; 2021 Mar; 51(3):703-713. PubMed ID: 33098668
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
17. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.
Du K; Wei S; Wei Z; Frederick DT; Miao B; Moll T; Tian T; Sugarman E; Gabrilovich DI; Sullivan RJ; Liu L; Flaherty KT; Boland GM; Herlyn M; Zhang G
Nat Commun; 2021 Oct; 12(1):6023. PubMed ID: 34654806
[TBL] [Abstract][Full Text] [Related]
18. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
19. Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.
Shklovskaya E; Pedersen B; Stewart A; Simpson JOG; Ming Z; Irvine M; Scolyer RA; Long GV; Rizos H
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230753
[TBL] [Abstract][Full Text] [Related]
20. Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma.
Chen S; Zhang L; Lin H; Liang Y; Wang Y
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
